Stay updated with breaking news from Inhalation Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from the EXPEDITE study of Remodulin® induction prior to Orenitram® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso® Inhalation Solution in... | April 18, 2023
Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.
To expand Lupin's portfolio of inhalation products in the US
Lupin has announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana® Inhalation Solution and Xopenex HFA® Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. for a purchase price of $75 million.
The acquisition of said brands will expand Lupin’s portfolio of Inhalation products.